iTonic Holdings Ltd Dossier
Qualitative Analysis
Business overview
iTonic Holdings Ltd (NASDAQ: ITOC), formerly known as Pheton Holdings Ltd until its corporate rebranding in January 2026, is a Beijing, China-based healthcare solutions provider specializing in treatment planning systems (TPS) and medical auxiliary supplies for brachytherapy. Operating primarily through its wholly owned subsidiary, Beijing Feitian Zhaoye Technology Co., Ltd., the company's flagship product is the Beijing Feitian Treatment Planning System (FTTPS). FTTPS is a proprietary, user-oriented software system designed to treat various malignant tumors by determining target volume, prescription dose, and dose distribution plans for radioactive particle implantation. Additionally, the company commercializes medical auxiliary supplies, including seed implant needles, computer workstations, and patient positioning devices.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Development of a next-generation AI-enabled Treatment Planning System (TPS) Cloud Platform through its 60%-owned subsidiary, Mili (Jiangsu) Medical Technology Co., Ltd. The platform aims to transform traditional standalone treatment planning software into a cloud-based collaboration platform integrating AI, medical data connectivity, and automated quality control.
Expected impact: Enables multi-location collaboration, standardizes clinical workflows, and enhances patient care coordination in nuclear medicine and radiation treatment planning.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To expand the company's footprint into the U.S. market and enter the rapidly growing home health sector by integrating iTonic's home-health AI, medical device automation, and clinical care platform.
Financial impact: Involved issuing 4,000,000 newly issued Class A ordinary shares to selling shareholders subject to performance milestones, plus warrants to purchase up to 3,000,000 additional Class A ordinary shares at an exercise price of $3.10.